Physician profile
Austin John Harmon
NPI 1528758265
$1,129.09
in general payments reported to CMS, 2019-2025
18 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $14.95 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $278.80 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $183.50 | 2025 | Krystexxa, Evenity, Repatha |
| Exact Sciences Corporation | $114.92 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $100.73 | 2025 | Trelegy Ellipta |
| Abbvie INC. | $92.91 | 2025 | |
| Lilly USA, LLC | $79.70 | 2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $44.02 | 2025 | |
| Pfizer INC. | $38.27 | 2025 | |
| Sumitomo Pharma America, INC. | $26.69 | 2025 | Gemtesa |
| Aimmune Therapeutics, INC. | $23.21 | 2025 | Zenpep |
| Astellas Pharma US INC | $21.00 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $20.07 | 2025 | |
| Merck Sharp & Dohme LLC | $19.95 | 2025 | |
| Renalytix Ai, INC. | $18.72 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Vertex Pharmaceuticals Incorporated | $17.89 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.22 | 2025 | Caplyta |
| Medtronic, INC. | $16.89 | 2025 | Minimed 780g |
| Currax Pharmaceuticals LLC | $14.60 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Harmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.